Wednesday, March 25, hear from Dr. Anthony M Magliocco, CEO and Founder of Protean BioDiagnostics, as he discusses the application of whole exome sequencing for guiding clinical trial enrollment for patients with cancer.
The remarkable advances in precision medicine are unfortunately not currently available to all patients, especially those being treated in community cancer settings. This growing “gap” is now challenging the health system to provide cost-effective, scalable, innovative solutions for underserved patients. Protean BioDiagnostics was founded to close this gap and accelerate access to precision oncology for all patients, regardless of where they live. To this end, Protean has created an adaptable and innovative framework for rapidly deploying the latest companion diagnostics. Protean’s simplification of universal access to complex diagnostics is poised to change the practice of precision oncology in the community and truly “close the gap.”
In this webinar, you will learn more about
Date: Wednesday, March 25, 2020
Time: 11 am EDT
The concept of precision medicine is beautifully simple: deliver the right treatment, every time, to the right patient. Making that concept a reality is more complex. Precision medicine is, after all, an entirely new approach to clinical medicine that leverages the power of big data and genomics to transform healthcare.
In a new on-demand webinar, Future of Genomics: The Precision Medicine Solution, our expert panel discusses how Aeon Global Health, the fastest growing clinical lab and healthcare services organization in the United States, partnered with QIAGEN to adopt an end-to-end automation solution that sped up their diagnostic output while lowering costs.
In 2013, when Aeon Global Health entered the hereditary cancer screening market, they knew that automation was critical to success. Together, QIAGEN Bioinformatics and Intel created a solution. By combining QIAGEN’s unparalleled expertise in genomics with Intel’s cutting-edge healthcare technology, the two companies enabled Aeon to provide faster, more comprehensive clinical insights than human cognition alone could permit. Today, one clinical geneticist at Aeon can process up to 50 tests per day.
Instead of taking weeks or months to make sense of a patient’s unique genetic profile, Aeon can now extract insights from colossal amounts of data in only a few minutes. And it’s not just the increase in efficiency that deserves attention. By partnering with Intel, QIAGEN has created an end-to-end solution that provides all workflow components, from analysis to interpretation to reporting, without having to hire hundreds of clinical geneticists and molecular pathologists, who would have to read reports and complete literature searches by hand. Clinical diagnostic test results are delivered quickly, accurately, and at a much lower cost.
As the amount of medical and biological data involved in medical diagnostics increases, so will the need for systems that help researchers, doctors and patients make sense of it. There are few medical advances as promising as precision medicine, and QIAGEN’s AI-based diagnostic tools—powered by Intel’s Scalable Solution Framework—are leading the way.
Join speakers Dr. Shawn Desai, Chief Technology Officer of Aeon Global Health, Dr. Ramon Felciano, Chief Technology Officer and Vice President of Strategy of QIAGEN Bioinformatics, and Kristina Kermanshahche, Global Director of Life Sciences at Intel Corporation, as they discuss how Aeon selected this powerful genomics solution and how you can build upon Aeon’s experience and accelerate your own path to success.
Watch Now — to learn how to put precision medicine on the fast track.
This July, we’re holding a special webinar series event showcasing a variety of aspects of NGS technology. Our wet-bench experts Matt Finley and Adam LaBonte will kick things off starting on July 6 with a 3-part series on hands-on considerations for using the QIAseq Targeted Panels. MicroRNA guru Jon Shaffer joins the fun on July 11 and 18 with a discussion of technology to drastically improve your miRNA-seq and a second presentation devoted to miRNA-seq from biofluids. On July 12 and 19, Dr. Lynne Mullen and Dr. Prakriti Mudvari will walk you through QIAGEN’s powerful bioinformatics solutions. Finally, to cap off the month, our Global Product Manager for NGS technologies, Sam Rulli, will present a 5-part series delving into digital NGS technology using Unique Molecular Indices for DNA-seq, RNA-seq and miRNA-seq, as well as single-cell NGS.
Check out the details and visit our registration pages here
Josh Deignan, Associate Director at UCLA Molecular Diagnostics Laboratories, presents this webinar on clinical genomic sequencing. He discusses where we’ve been, where we are, and also have a few comments on where the field of molecular diagnostics and clinical genomic sequencing might be headed in the future.
Learn how he sees the challenges with clinical NGS - how to validate the accuracy of NGS tests and how results are actually being interpreted.
Clinical genomic sequencing: Where we’ve been, where we are, and where we’re going
Presenter: Josh Deignan, Ph.D., F.A.C.M.G, Associate Director, UCLA Molecular Diagnostics Laboratories
Each month we’re hosting a series of webinars introducing Ingenuity Pathway Analysis.
The first webinar each month is giving you an introduction to IPA while the following sessions are focusing on uploading you data or interpreting your results. Our experts Dr. Lynne Mullen and Dr. Jasmin Droege are hosting the webinars in U.S. and EU time zones, respectively.
You can find all our IPA support webinars here:
If you're interested in watching other webinars or videos, you can find our complete collection on tv.qiagenbioinformatics.com.
How much compute power do you need to analyze 10 gene panels, exomes, or genomes each day? What about 1,000 genomes each week?
Questions about compute infrastructure are among the most common we hear from our customers, and this has been the primary motivator for our collaboration with Intel. Together, we’ve been working to support affordable, massively scalable whole-genome analysis based on Intel’s world-class infrastructure and our industry-leading analysis tools.
Earlier this year we released the reference architecture that came from this collaboration, and you can learn more about it in the webinar below featuring Michael McManus, Senior Health & Life Sciences Solution Architect at Intel, and Mikael Flensborg, Director and Solution Lead for QIAGEN Bioinformatics. The speakers will update you on the new architecture, which combines our Biomedical Genomics Solution with the Intel Scalable System Framework. They’ll also share advice on sizing and building a genomics cluster based on data-generation needs, as well as how to scale the cluster as demand changes.
The solution represents some of the code optimization work that Intel has focused on lately, teaming up with industry leaders such as QIAGEN Bioinformatics to improve algorithms based on the latest multi-core chip architecture. As genome analysis tools become increasingly complex — newer haplotype-aware callers, for instance, are far more computationally intense than older generations of variant callers — there is greater need for scientists to become experts in computational infrastructure. With solutions like the QIAGEN/Intel reference architecture, we alleviate that burden by recommending a scalable, easily managed system that allows users to focus instead on the science.
For example, this system meets the computational and analysis demands of Illumina’s HiSeq X Ten while providing whole-genome analysis for as little as $22 per genome. With Intel’s 32-node cluster, researchers can save as much as $1.3 million in total ownership costs compared to a vendor-recommended BWA+GATK variant calling pipeline run on an 85-node cluster.
Learn more about our High volume sequencing solution
Reference Architectures for the QIAGEN Biomedical Genomics Solution
https://clcbio.23video.com/12438081.ihtml/player.html?token=9c8598703736f4ebfb60db5c2669f27b&source=embed&photo%5fid=14250926
During the coming months we’ll be hosting a series of webinars introducing CLC Genomics Workbench.
Our first webinar in the series, touches upon data import, the toolbox, workflows, and data visualization. Senior Bioinformatics Engineer Ajay Athavale introduces the workbench through an example of identifying and comparing variants and visualizing those in a genomic context together with sequencing reads and annotations:
Webinars recording is available below.
More webinars will follow and you can sign up for our upcoming webinars here.
https://clcbio.23video.com/v.ihtml/player.html?token=73eeceac9f79325280aaff3210ba9e88&source=embed&photo%5fid=13502249Webinar: CLC Genomics Workbench epigenomics tools
We have revolutionized how epigenomics data is efficiently processed, identified and interpreted, and in this webinar we'll show you how to fully benefit from the advances of CLC Genomics Workbench to get deep insight into the biology of:
Learn more about the epigenomics features of CLC Genomics Workbench
https://clcbio.23video.com/v.ihtml/player.html?token=133f6d868a99fc77492cca4094146d44&source=embed&photo%5fid=13493075
Part four of our webinar series on liquid biopsies:
Circulating cell-free DNA purification, sequencing and data interpretation
Identification and monitoring of cancer mutations of circulating cell-free DNA (cfDNA) is a key application in liquid biopsy. In the webinar series, we discuss various new technologies and present a complete sample to insight workflow for cfDNA mutation analysis. In this webinar, we show how mutations can be best identified from this type of data and how they can be interpreted. Anika Joecker, Global Solution Product Manager Bioinformatics, Clinical Program, present our solutions for analysis and interpretation of cell free DNA.
https://clcbio.23video.com/v.ihtml/player.html?token=1d44ef16da780f0a29b214aad388d7cd&source=embed&photo%5fid=13428465Webinar: Transcriptome analysis of pancreatic cancer exosomes involved in metastatic progression
Pancreatic cancer is one of the most lethal malignancies with a poor prognosis. Liquid biopsies are non-invasive methods for diagnostics to detect early stage cancer resulting in more successful treatment. One liquid biopsy technique is the detection of RNA from tumor-derived exosomes.
In this webinar you can learn how bioinformatics solutions can be used to analyze and interpret RNA-sequencing results from these exosome experiments, providing additional hypothesis on regulatory networks and potential isoforms of biological significance. We’ll examine the transcriptome of pancreatic tumor-derived exosomes that induce the formation of a liver metastatic niche, and demonstrate how our solutions can provide deep biological understanding in this process.
Find out how to:
https://clcbio.23video.com/v.ihtml/player.html?token=2d8ebf27b60d36957a4ba82940f712e0&source=embed&photo%5fid=13222910
